Compare ARMP & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARMP | IMMR |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 215.8M |
| IPO Year | 1996 | 1999 |
| Metric | ARMP | IMMR |
|---|---|---|
| Price | $5.41 | $7.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $15.00 | $13.50 |
| AVG Volume (30 Days) | 93.2K | ★ 336.6K |
| Earning Date | 05-07-2026 | 04-13-2026 |
| Dividend Yield | N/A | ★ 5.11% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $35,013,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $54.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $5.25 |
| 52 Week High | $14.98 | $8.05 |
| Indicator | ARMP | IMMR |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 47.84 |
| Support Level | $5.12 | $7.34 |
| Resistance Level | $5.63 | $7.93 |
| Average True Range (ATR) | 0.47 | 0.20 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 84.37 | 13.28 |
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.